{"id":1039,"date":"2014-10-06T11:00:07","date_gmt":"2014-10-06T09:00:07","guid":{"rendered":"http:\/\/www.satt.fr\/?p=1039"},"modified":"2017-11-13T16:54:35","modified_gmt":"2017-11-13T15:54:35","slug":"clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/","title":{"rendered":"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Cette licence est issue d\u2019un d\u00e9veloppement financ\u00e9 \u00e0 hauteur de 260 K\u20ac par la SATT Sud Est. Elle porte sur l\u2019utilisation d\u2019une nouvelle classe de mol\u00e9cules pour le traitement du cancer (syndromes my\u00e9lodysplasiques r\u00e9sistants \u00e0 l\u2019azacitidine et\/ou \u00e9volutifs en leuc\u00e9mies aig\u00fces my\u00e9lo\u00efdes) et un test compagnon. La licence se poursuivra sous forme d\u2019un partenariat scientifique entre les \u00e9quipes de recherche et CleveXel Pharma, jusqu\u2019en phase clinique<\/strong><\/p>\n<ul>\n<li><a title=\"Communiqu\u00e9 de presse SATT Sud Est - CleveXel Pharma\" href=\"https:\/\/www.sattse.com\/2014\/10\/presse-clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/\">D\u00e9couvrez la suite sur le site de la SATT Sud Est<\/a><\/li>\n<li><a title=\"Communiqu\u00e9 de presse SATT Sud Est - CleveXel Pharma\" href=\"https:\/\/www.sattse.com\/wp-content\/uploads\/2014\/10\/CP_SATTSudEst_CleveXelPharma_61014.pdf\">T\u00e9l\u00e9chargez le communiqu\u00e9 de presse<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Cette licence est issue d\u2019un d\u00e9veloppement financ\u00e9 \u00e0 hauteur de 260 K\u20ac par la SATT Sud Est. Elle porte sur l\u2019utilisation d\u2019une nouvelle classe de mol\u00e9cules pour le traitement du cancer (syndromes my\u00e9lodysplasiques r\u00e9sistants \u00e0 l\u2019azacitidine et\/ou \u00e9volutifs en leuc\u00e9mies aig\u00fces my\u00e9lo\u00efdes) et un test compagnon. La licence se poursuivra sous forme d\u2019un partenariat scientifique [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[535],"tags":[90,115,123,135,143,153,170,29,171,31,172,38,42,47,50,55,56,88],"class_list":["post-1039","post","type-post","status-publish","format-standard","hentry","category-reussites","tag-propriete-intellectuelle","tag-paris","tag-nice","tag-sophia-antipolis","tag-cnrs","tag-chu-de-nice","tag-inserm","tag-satt-sud-est","tag-oncologie","tag-transfert-de-technologies","tag-universite-nice-sophia-antipolis","tag-recherche","tag-diagnostic","tag-marseille","tag-communique-de-presse","tag-sante","tag-technologies-du-vivant","tag-brevet"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"redacteur SATT\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/\"},\"author\":{\"name\":\"redacteur SATT\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/a6836c00a1284a8188e1a05deb2a5e5c\"},\"headline\":\"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est\",\"datePublished\":\"2014-10-06T09:00:07+00:00\",\"dateModified\":\"2017-11-13T15:54:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/\"},\"wordCount\":125,\"keywords\":[\"propri\u00e9t\u00e9 intellectuelle\",\"paris\",\"nice\",\"sophia antipolis\",\"cnrs\",\"chu de nice\",\"inserm\",\"SATT Sud Est\",\"oncologie\",\"transfert de technologies\",\"universit\u00e9 nice sophia antipolis\",\"recherche\",\"diagnostic\",\"marseille\",\"communiqu\u00e9 de presse\",\"sant\u00e9\",\"technologies du vivant\",\"brevet\"],\"articleSection\":[\"R\u00e9ussites\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/\",\"url\":\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/\",\"name\":\"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"datePublished\":\"2014-10-06T09:00:07+00:00\",\"dateModified\":\"2017-11-13T15:54:35+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/a6836c00a1284a8188e1a05deb2a5e5c\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/a6836c00a1284a8188e1a05deb2a5e5c\",\"name\":\"redacteur SATT\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/redacteur\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/","twitter_misc":{"Written by":"redacteur SATT"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/"},"author":{"name":"redacteur SATT","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/a6836c00a1284a8188e1a05deb2a5e5c"},"headline":"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est","datePublished":"2014-10-06T09:00:07+00:00","dateModified":"2017-11-13T15:54:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/"},"wordCount":125,"keywords":["propri\u00e9t\u00e9 intellectuelle","paris","nice","sophia antipolis","cnrs","chu de nice","inserm","SATT Sud Est","oncologie","transfert de technologies","universit\u00e9 nice sophia antipolis","recherche","diagnostic","marseille","communiqu\u00e9 de presse","sant\u00e9","technologies du vivant","brevet"],"articleSection":["R\u00e9ussites"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/","url":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/","name":"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"datePublished":"2014-10-06T09:00:07+00:00","dateModified":"2017-11-13T15:54:35+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/a6836c00a1284a8188e1a05deb2a5e5c"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/clevexel-pharma-acquiert-une-licence-dexploitation-de-2-brevets-portant-sur-le-diagnostic-et-le-traitement-des-syndromes-myelodysplasiques-apres-maturation-par-la-satt-sud-est\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"CleveXel Pharma acquiert une licence d\u2019exploitation de 2 brevets portant sur le diagnostic et le traitement des syndromes my\u00e9lodysplasiques, apr\u00e8s maturation par la SATT Sud Est"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/a6836c00a1284a8188e1a05deb2a5e5c","name":"redacteur SATT","url":"https:\/\/www.satt.fr\/en\/author\/redacteur\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/1039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=1039"}],"version-history":[{"count":1,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/1039\/revisions"}],"predecessor-version":[{"id":4856,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/1039\/revisions\/4856"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=1039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=1039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=1039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}